Florida Cancer Specialists Press Release


Dr. Lucio Gordan Accepts Term on Editorial Board of Journal of Clinical Oncology - Clinical Cancer Informatics

Florida Cancer Specialists’ Gainesville Physician Lends Expertise to Leading Oncology Publication

Gainesville, FL – May 17, 2016……… Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Dr. Lucio Gordan, who practices at the Gainesville Cancer Center of FCS, has accepted a new term on the Editorial Board of the Journal of Clinical Oncology Clinical Cancer Informatics (JCO CCI). The Journal of Clinical Oncology, published by the American Society of Clinical Oncology (ASCO), is a global journal for disseminating significant clinical oncology research. According to ASCO, the new JCO CCI is an “online-only journal publishing high quality studies representing actionable knowledge, clinical and are delivery research validations and new research hypotheses, based on the growing knowledge base represented by EHR (Electronic Health Records), registry, and clinical trials data to genomics databases.”

Dr. Gordan, who serves on the Executive Board of FCS and as Medical Co-Director of Health Information Technology, said, “I am honored to be asked to serve on the editorial board for Clinical Cancer Informatics. The journal publishes reviews, editorials, and commentaries on data studies relevant to cancer care, as well as papers on the methodology and interpretation of clinical cancer informatics research. This is of critical importance in translating oncology research into new standards for improving patient care.”

FCS CEO Brad Prechtl noted, “Dr. Gordan’s work in this area represents the strong focus we have to help develop better systems and platforms for sharing the rapidly-growing knowledge base in oncology. His selection to the editorial board of this highly-respected journal is a further indication of his exceptional expertise and experience. FCS is extremely proud and appreciative to have his caliber of physician leaders in our organization.”

Dr. William Harwin, Founder and President of FCS, added, “In addition to providing world-class clinical care to our patients, FCS is also committed to clinical trials research, including a Phase 1 Clinical Trials Program that rivals many academic medical centers. Being able to disseminate the data gathered in our clinical research programs is of utmost importance and Dr. Gordan’s selection to the editorial board of JCO CCI puts him on the cutting-edge of this rapidly advancing area of information technology and helping to transform scientific research into new cancer treatments.”


About Florida Cancer Specialists & Research Institute: (FLCancer.com)
Founded in 1984, Florida Cancer Specialists & Research Institute (FCS) is the largest independent medical oncology/hematology practice in the United States. With over 180 physicians, 150 nurse practitioners and physician assistants and over 90 locations in our network, we are committed to providing world-class cancer care in community-based settings close to home.

Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, FCS offers patients access to more clinical trials than any private oncology practice in Florida. 70% of new cancer drugs approved in 2015 for use in the U.S. were studied in clinical trials conducted with FCS participation*. Our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report. Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan-Kettering, the physicians of Florida Cancer Specialists provide leadership and consultation in the state's leading hospitals.

FCS serves patients on the Gulf Coast from Naples to the greater Tampa Bay area, north as far as Tallahassee, in Orlando and surrounding Central Florida communities, and on the East Coast in Daytona/Palm Coast, Vero Beach/Sebastian and in Palm Beach County.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research and cutting-edge technologies that help advance targeted treatments and genetically-based immunotherapies, and embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.

* Prior to approval

For More Information, Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer -

Double Diamond Marketing + Communications
Angela Evans -
Elaine Ganick -